Fingerprint Cards AB
Fingerprint Cards AB's slim mobile sensor first to achieve EMVCo approval for secure mobile payments
Fingerprint Cards AB (Fingerprints™) today announced that its slim mobile sensor, FPC1541, has been successfully evaluated in line with the EMV® Consumer Device Cardholder Verification Methods (CDCVM) Security Requirements
. This is the first announced fingerprint sensor for mobile devices to achieve this approval, demonstrating the quality, security and performance of Fingerprints’ sensor when used to authenticate payments on mobile devices.
EMVCo facilitates worldwide interoperability and acceptance of secure payment transactions, and is supported by banks, merchants, payment networks and other industry stakeholders. The EMVCo CDCVM requirements respond to the growing use of biometric authentication on consumer-owned mobile devices for payments, including fingerprint, iris, voice, and facial recognition. They aim to promote confidence and consistency in the industry and define several high-level biometric performance requirements including false acceptance and false rejection rates.
“Biometrics and mobile payments are becoming synonymous due to the combination of security and convenience. These new requirements from EMVCo are a testament to the increasingly important, central role of biometrics in this ecosystem,” comments Ted Hansson, SVP Mobile Business Line at Fingerprints. “Fingerprints has long been a proud collaborator with the payments industry and champions of standardization. This achievement is an important marker of the quality and performance of our sensors and shows that even our design-enabling small and slim sensors meet the needs of the rigorous payments world.”
Fingerprints is an active participant in both GlobalPlatform and FIDO Alliance, both submitting bodies to the CDCVM requirements. The slim FPC1541 sensor for side-mounting can double as power button and volume control, enabling greater design flexibility and an enhanced user-experience. Learn more here .
*EMV® is a registered trademark in the U.S. and other countries and an unregistered trademark elsewhere. The EMV trademark is owned by EMVCo, LLC.
For further information, please contact:
Ted Hansson, Senior VP BL Mobile
Investor Relations:
+46(0)10-172 00 10, investrel@fingerprints.com
Press:
+46(0)10-172 00 20, press@fingerprints.com
About Fingerprints
Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and seamless universe, where you are the key to everything. Our solutions are found in hundreds of millions of devices and applications, and are used billions of times every day, providing safe and convenient identification and authentication with a human touch. For more information visit our website
, read our blog
, and follow us on Twitter
. Fingerprints is listed on Nasdaq Stockholm (FING B).
Attachment
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Synairgen plc25.1.2021 08:06:49 CET | Press release
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
F. Hoffmann-La Roche Ltd25.1.2021 08:06:08 CET | Press release
Roche renews partnership with Sysmex to deliver haematology testing solutions
Royal Philips25.1.2021 08:06:08 CET | Press release
Philips delivers Q4 sales of EUR 6.0 billion, with 7% comp. sales growth; income from cont. operations increases to EUR 608 million, Adjusted EBITA margin improves 110 bps to 19.0%, and operating cash flow increases to EUR 1,305 million
F. Hoffmann-La Roche Ltd25.1.2021 08:02:27 CET | Press release
Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration
Junshi Biosciences25.1.2021 08:01:47 CET | Press release
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
Montreal Heart Institute23.1.2021 07:02:08 CET | Press release
Colchicine reduces the risk of COVID-19-related complications
Zealand Pharma22.1.2021 22:06:25 CET | Press release
Zealand Pharma announces update to 2020 financial guidance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom